ADIL — ADIAL PHARMACEUTICALS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1513525 ·
Last close
$4.22
Market Cap
$12.38M
52W High
$10.75
52W Low
$1.31
ADV30
60,867
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -52,025,000 | -51,989,000 | 29,089,000 | 28,712,000 | 67,466,000 |
| Mar 2026 | 0 | — | -2,001,481 | -2,022,392 | 5,227,321 | 4,584,100 | 1,510,071 |
| Dec 2025 | 0 | — | -1,885,379 | -1,996,163 | 6,673,367 | 5,881,217 | 1,396,909 |
| Sep 2025 | 0 | — | -1,764,078 | -1,793,651 | 5,659,847 | 4,606,289 | 1,154,756 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,519,611
Investing CF
$0
Financing CF
$8,737,931
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.50
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-91,994,886
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-7,533,650
Pretax Income TTM
$-7,770,762
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,799,462 | -7,977,171 | 6,673,367 | 1,396,909 | 5,276,458 | -6,492,603 |
| Dec 2024 | 0 | -8,284,457 | -13,197,451 | 5,043,942 | 975,858 | 4,068,084 | -6,922,306 |
| Dec 2023 | 0 | -6,887,947 | -5,123,341 | 4,736,605 | 653,076 | 4,083,529 | -6,806,809 |
| Dec 2022 | 0 | -10,859,475 | -12,731,416 | 5,732,804 | 2,456,310 | 3,276,494 | -11,185,985 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-7.45
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BFRG | BullFrog AI Holdings, Inc. | $12.35M | $0.67 | — |
| GTBP | GT Biopharma, Inc. | $12.43M | $6.89 | — |
| BLRX | BioLineRx Ltd. | $12.61M | $2.60 | — |
| VTGN | Vistagen Therapeutics, Inc. | $11.98M | $0.27 | — |
| CALC | CalciMedica, Inc. | $11.95M | $1.75 | — |
News headlines (Yahoo Finance, 1h cache)
Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
2026-08-25 20:05 · Yahoo
Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing
2026-06-16 12:00 · Yahoo
ADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel Rally
2026-06-11 17:04 · Yahoo
Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing
2026-06-11 15:43 · Yahoo
Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update
2026-05-11 12:30 · Yahoo
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
2026-04-29 13:07 · Yahoo
Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program
2026-04-27 12:47 · Yahoo
Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial
2026-04-22 13:35 · Yahoo
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other
2026-06-08 17:00 · Yahoo
Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update
2026-08-17 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.